 BACKGROUND: Sorafenib drug approved treatment hepatocellular carcinoma (HCC). bioenergetic propensity cancer cells correlated anticancer drug resistance, correlation unclear sorafenib resistance HCC. METHODS: Six sorafenib-naive HCC cell lines one sorafenib-resistant HCC cell line (Huh-7R; derived sorafenib-sensitive Huh-7) used. bioenergetic propensity calculated measurement lactate presence absence oligomycin. Dichloroacetate (DCA), pyruvate dehydrogenase kinase (PDK) inhibitor, siRNA hexokinase 2 (HK2) used target relevant pathways cancer metabolism. Cell viability, mitochondrial membrane potential, sub-G1 fraction measured vitro efficacy. Reactive oxygen species (ROS), adenosine triphosphate (ATP) glucose uptake also measured. subcutaneous xenograft mouse model used vivo efficacy. RESULTS: bioenergetic propensity using glycolysis correlated decreased sorafenib sensitivity (R(2)=0.9067, among sorafenib-naive cell lines; P=0.003, compared Huh-7 Huh-7 R). DCA reduced lactate production increased ROS ATP, indicating activation oxidative phosphorylation (OXPHOS). DCA markedly sensitised sorafenib-resistant HCC cells sorafenib-induced apoptosis (sub-G1 (combination vs sorafenib): Hep3B, 65.4+/-8.4% vs 13+/-2.9%; Huh-7 R, 25.3+/- 5.7% vs 4.3+/-1.5%; P<0.0001), whereas siRNA HK2 not. Sorafenib (10 mg kg(-1) per day) plus DCA (100 mg kg(-1) per day) also resulted superior tumour regression sorafenib alone mice (tumour size: -87% vs -36%, P<0.001). CONCLUSION: bioenergetic propensity potentially useful predictive biomarker sorafenib sensitivity, activation OXPHOS PDK inhibitors may overcome sorafenib resistance HCC.